Skip to content
OpenCapital
Get started

C4 Therapeutics CCCC Q4 2024 Annual earnings

Reported February 27, 2025 · Before market open

Revenue$5.2MBeat by $1.8MDiluted EPS-$0.49Miss by $0.05
Revenue estimate$3.3M
EPS estimate-$0.44

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$8.2M
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$6.2MBeat by $1.8MQ4 2025$11.0MBeat by $5.6MQ3 2025$11.2MBeat by $6.8MQ2 2025$6.5MMiss by $337.0KQ1 2025$7.2MBeat by $3.7M
Q4 2024$5.2MBeat by $1.8M

Diluted EPS

Q1 2026-$0.20Beat by $0.05Q4 2025-$0.18Beat by $0.13Q3 2025-$0.44Beat by $0.03Q2 2025-$0.37Beat by $0.01Q1 2025-$0.37Beat by $0.11
Q4 2024-$0.49Miss by $0.05

Ask the moment C4 Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did C4 Therapeutics report Q4 2024 earnings?
C4 Therapeutics (CCCC) reported Q4 2024 earnings on February 27, 2025 before market open.
What were C4 Therapeutics's Q4 2024 revenue and EPS?
C4 Therapeutics reported revenue of $5.2M and diluted EPS of $-0.49 for Q4 2024.
Did C4 Therapeutics beat estimates in Q4 2024?
Revenue beat the consensus estimate of $3.3M by $1.8M. EPS missed the consensus estimate of $-0.44 by $0.05.
Where can I find C4 Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001628280-25-008433) directly on SEC EDGAR. The filing index links above go to sec.gov.